So far, 21 COVID-19 clinical trials have been completed – with the majority of those sponsored by Chinese hospitals and in the Wuhan province, says the outlet. However, as of yet, few outstanding possible drug candidates have emerged.
Scotty Chung-Siu, Senior Analyst at GlobalData, commented: “In the trials that have been completed thus far, most of the drugs being used as a primary intervention are off-label and have been approved for the treatment of a different infectious disease. For example, hydroxychloroquine was first approved for the treatment of malaria. Despite interim results showing reduction of COVID-19 virus load from an ongoing trial of hydroxychloroquine with azithromycin conducted in France’s Aix Marseille University, one of the completed clinical trials investigating hydroxychloroquine in combinations of antivirals did not achieve primary endpoints. The other trial investigating hydroxychloroquine alone did not disclose results.”
Over 60 percent of the completed clinical trials are either in very early stage or late stage. The majority of the primary interventions used in the nine completed trials were small molecules...
Read the full text on the site GMPnews.Net